Our series describes more durable disease control in gangliogliomas with high-grade transformation treated with BRAF-targeted therapy compared with chemoradiation with temozolomide and raises questions regarding the optimal sequencing of treatment in recurrent/unresectable disease, particularly in cases where molecular characterization is predictive of a lesser response to alkylating chemotherapy. Here, BRAF is linked to ganglioglioma.